The Moderna vaccine decreases the production of antibodies to the nucleocapsid in a dose dependent fashion in those who acquire COVID after vaccination. Four months after injection, 40% of vaccinated participants who acquired COVID after the second injection produced antibodies to the nucleocapsid, compared to 93% of those who received … Continue reading Report 34: Understanding C-19 Vaccine Efficacy Clinical Trial in Lay Terms